Morgan Stanley Spring Works Therapeutics, Inc. Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SWTX
# of Institutions
238Shares Held
69.8MCall Options Held
144KPut Options Held
257K-
Vanguard Group Inc Valley Forge, PA6.71MShares$281 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$235 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.84MShares$161 Million4.54% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.52MShares$147 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA3.42MShares$143 Million5.82% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $2.61B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...